Furuyametals Lifts FY2027 Forecast on Precious Metals Demand Surge

Furuyametals Co., Ltd. (TSE:7826), Japan’s leading manufacturer and recycler of precious metals and rare metals, reported exceptional third-quarter results for the fiscal year ending June 2026, with revenue surging 83.1% year-over-year to JPY 74.7bn and operating profit nearly doubling to JPY 17.3bn. The company has raised its full-year guidance, signaling confidence in sustained demand from data center infrastructure and medical device applications.

Business Overview

Furuyametals manufactures, processes, and recovers precious metals including platinum and rare metals, with particular strength in refining, recasting, and thin-film technologies. The company serves semiconductor, electronics, chemical, and recycling markets across Japan and internationally, positioning itself as a critical supplier to high-value industrial applications.

Analysis: Margin Expansion Outpaces Revenue Growth

The standout feature of Furuyametals’ Q3 performance is the disproportionate profit expansion: operating profit grew 109.4% while revenue expanded 83.1%, reflecting both operational leverage and favorable product mix dynamics. The 23.2% operating margin—achieved across a diversified portfolio—underscores the company’s technological differentiation and pricing power in specialty materials.

This margin profile reflects three concurrent drivers. First, the thin-film segment, which supplies hard-disk sputtering targets for data center infrastructure, expanded 38.0% year-over-year with a 50.8% gross margin, directly benefiting from accelerating cloud and AI infrastructure investment. Second, the electronics segment—serving medical imaging (iridium crucibles for scintillator production) and communications infrastructure—grew 54.3%, anchored by counter-cyclical demand from healthcare and telecom capex. Third, the fine chemicals and recycling segment, despite a 2.0% revenue decline, achieved a 29.9% gross profit increase, driven by recovery in caustic soda electrode applications and early signs of organic electroluminescence demand recovery.

The equity ratio improved to 58.9% from 52.0%, indicating balance-sheet strengthening through retained earnings and debt reduction—a structural improvement that reduces financial risk and provides flexibility for future investments or shareholder returns.

A notable headwind is the fine chemicals segment’s revenue contraction, attributed to sluggish chemical plant orders amid “gradual” recovery in the Chinese economy, as noted in the company’s earnings flash report (kessan tanshin). Additionally, the company’s profitability remains partially dependent on precious metals price appreciation and favorable yen weakness, both of which carry reversal risk.

Next Year Guidance

Management’s full-year guidance implies continued momentum, with operating profit expected to reach JPY 22.5bn (+135.9% versus Q3 cumulative results). The implied operating margin of 23.4% suggests conservative profit rate assumptions despite the strong revenue growth trajectory. This guidance reflects management’s confidence in data center demand persistence and medical device cycle strength, though it incorporates cautious assumptions around Chinese economic recovery and geopolitical headwinds.

What to Watch

Data Center Cycle Sustainability: The thin-film segment’s performance is now the primary profit driver. Any moderation in cloud capex or hard-disk demand would directly impact earnings trajectory. Monitor quarterly commentary on order backlogs and customer inventory levels.

Precious Metals Price Volatility: With significant exposure to platinum, iridium, and other rare metals, sharp declines in commodity prices could compress margins asymmetrically. The current profit expansion is partially attributable to favorable commodity pricing; investors should track London Metals Exchange quotations.

Chinese Industrial Recovery: Management flagged cautious near-term outlook for chemical plant orders. Acceleration in Chinese capex cycles—particularly in semiconductors and chemicals—could unlock upside in the fine chemicals segment and validate the aggressive full-year guidance.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.